Immunotherapy Resistance in Melanoma Linked to Gene Expression Program

Nov 01, 2018

|

NEW YORK (GenomeWeb) – Researchers have teased out a gene expression program that is associated with resistance to immunotherapy in melanoma. Inhibiting this program could improve treatment response.

While immunotherapies like immune checkpoint inhibitors have led to sometimes-dramatic responses in a portion of cancer patients, others don't respond to the treatment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

A Personalized, Tumor-Informed Approach to Detect Molecular Residual Disease With High Sensitivity and Specificity

BCR-ABL1 Minor Breakpoint (e1a2) Monitoring Using an Analytically Validated Multiplex Assay

Modifications to RNA Isolation Protocols Meet Requirements for Modern CML Monitoring of BCR-ABL1 Transcript Levels

Aug

24

Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug

25

Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep

10

Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Oct

08

Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Menu

Immunotherapy Resistance in Melanoma Linked to Gene Expression Program

To read the full story....

Breaking News

FDA Approves Genentech's Tecentriq, Cotellic, Zelboraf for BRAF V600-Mutated Melanoma

European Commission Approves Novartis' Piqray, Fulvestrant for PIK3CA-Mutated Breast Cancer

Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications

Guardant Health Enters CDx Collaboration With Radius Health for Elacestrant in HER2- Breast Cancer

Bristol Myers Squibb, Bluebird Bio Submit Application to FDA for Multiple Myeloma CAR T-Cell Therapy

FDA to Review Two New Applications for Merck's Keytruda in Triple-Negative Breast Cancer

Featured White Papers

Utility of Novel RNA-Based Tools in Oncology Drug Development

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

What's Popular?

Merus, Elevation Oncology Advance Drug Candidates Targeting NRG1 Fusion-Positive Cancers

European Commission Approves Novartis' Piqray, Fulvestrant for PIK3CA-Mutated Breast Cancer

Bristol Myers Squibb, Bluebird Bio Submit Application to FDA for Multiple Myeloma CAR T-Cell Therapy

FDA to Review Two New Applications for Merck's Keytruda in Triple-Negative Breast Cancer

FDA Approves Genentech's Tecentriq, Cotellic, Zelboraf for BRAF V600-Mutated Melanoma

Sponsorships